Canadian Federal Research Bureau will give researchers $3 million to explore the benefits of using psilocybin for the treatment of mental illness.
Last week, the Canadian Institutes of Health Research (CIHR) a grant application to fund psychedelic-assisted psychotherapy research for three specific mental illnesses.
The study supports Phase 1 or 2 randomized clinical trials of relevance to the use of psilocybin to treat dependence or substance use disorders, major depressive disorder and end-of-life mental health problems in patients with advanced cancer.
The aim is to strengthen the scientific base and expand research through new clinical trials.
Opportunities to fund psilocybin research in Canada
Funding will be provided by the Canadian Drugs and Substances Strategy (CDSS), led by Health Canada and in collaboration with the CIHR Institute of Neurosciences, Mental Health and Addiction (CIHR-INMHA).
“The current funding opportunity will expand the scientific base around psilocybin-assisted psychotherapy to inform practical policies and regulations aimed at improving the health of Canadians and people in Canada experiencing psychiatric disorders”, reads the announcement of the financing.
The $3 million total fund will be split into three grants, with the maximum amount per grant being $500.000 per year for up to two years for a total of $1 million per grant each studying a mental disorder.
“It is strongly encouraged that people with lived and/or life experiences are included in the research team to participate, as appropriate, in the design, implementation, mobilization of knowledge and/or other aspects of the research process”, is the description of the financing.
The application deadline is September 6, and the application deadline ends October 4. Financing will start at the beginning of March 2023.
The CIHR will host webinars to support applicants with the requirements of this funding and answer questions, the first of which will begin on June 9.